Endobronchial brachytherapy (EBBT) involves placing a radioactive source near a tumor to deliver high doses of radiation directly to it. EBBT is used palliatively to relieve symptoms from airway tumors by reducing tumor size. It can be performed using high or low dose rate brachytherapy via bronchoscopy. EBBT is effective at improving symptoms like hemoptysis and airway patency in 70% of patients for at least 6 months. It is also used to prevent restenosis in benign airway stenosis. While generally well-tolerated, risks include radiation bronchitis, stenosis, and fistula formation.
Overview of EBBT, presented by Dr. Tinku Joseph, DM Resident, at AIMS, Kochi, Malaysia.
Contents outline: Overview, Technique, Types, Indications, and Complications of EBBT.
EBBT involves placing radioactive sources near tumors for high-dose radiation, mainly as palliative therapy.
Goal of EBBT is to reduce tumor size and relieve airway symptoms, offering local radiation benefits.
Steps include patient selection, planning, and technique for radioactive source placement and monitoring.
Brachytherapy dose rates based on radionuclide characteristics: HDR, MDR, LDR, and ULDR.
Details on isotopes capable of brachytherapy applications in various medical fields.
Details on HDR efficacy: delivers 10-12 Gy/hr, with the total dose ranging from 5 to 40 Gy.
LDR delivers <2 Gy/hr, total doses 1500 to 5000 Gy; more cumbersome than HDR and less favored.
Indications for EBBT primarily include palliative treatment for obstructing lung tumors.
Focus on relieving obstructive symptoms in non-surgical candidates; efficacy ranges from 20-100%.Management of airway obstruction using EBBT; highlights symptom improvement rates.
Application of EBBT in recurrent tracheal stenosis to minimize restenosis rates.
Conditions that absolutely contraindicate EBBT; concerns include risks of fistula and obstruction.
Conditions relative to the procedure that increase risk, highlighting major vessel involvement.
Potential complications from EBBT measured <5%, with early and late risks identified.
EBBT is effective for palliative care of lung tumors; combines well with other treatments for improved outcomes.
Endobronchial Brachytherapy (EBBT)
Placement of a radioactive source within or in
close proximity to a malignancy in order to provide
high doses of radiation in close proximity to the
tumor.
Palliative therapy
Recently-: need for this technique has declined.
4.
Goal-:
Reduction intumor size so that airway symptoms can
be relieved.
Compared with (EBRT), EBBT - local radiation is
provided to the lesion (spares other tissues).
Technique
5.
1. Selection ofpatients
2. Planning phase
3. FOB/Rigid with or without MV
support
4. Placement of Radioactive source
(Ir-192)
5. Fluroscopy
6. HDR/LDR given
Technique
Radiation Type
Doserate of brachytherapy depends upon the energy
and rate of decay of the radionuclide used.
Commonly used-: Iridium192
• According to dose rate
1) High dose rate (HDR)-
- >12 Gy/Hr
2) Medium dose rate (MDR)
- 2-12 Gy/Hr
3)Low dose rate (LDR) -
- 0.4 -2 Gy/Hr
4)Ultra low dose rate (ULDR)-
-0.01-0.3 Gy/Hr
13.
ISOTOPES USED INBRACHYTHERAPY
can be embedded in
Surface Applicator- placed directly on surface of tumor eg. Hard
palate, skin, ocular
Intracavitory- inserted into specially designed apparatus that is
placed into body cavity eg. Gynec.malign, nasopharynx
Intraluminal- Various organs with lumen
(Oesophagus, endobronchial, biliary etc.)
Interstitial- Directly through tissues encompassing tumor
Intravascular- coronaries, peripheral art. internal mammary etc.
14.
10 to12 Gray (Gy)/hour,
Total dose - ranging from 5 to 40 Gy,
Dose per session (fraction) varying from 3 to 10 Gy.
Treated every 1-2 weeks (takes few mins)
HDR/LDR:
Treatment times are shorter
outpatient procedure.
Increase procedure efficiency,
Reduce treatment cost.
Simpler and safer therapy.
Radiation Type- HDR
16.
Radiation Type- LDR
Delivers less than 2 Gy/hour
Total dose of 1500 to 5000 Gy,
Given over a few days (usually up to three days)
Disadvantages:
Manual manipulation of the radionuclide
30 to 70 hours of continuous treatment,
Cumbersome radiation protection measures
Catheter has to be left in place for the few days of
administration.
17.
Inpatient procedure
Catheter displacement
More costly than HDR EBBT
Largely fallen out of favor.
Radiation Type- LDR
18.
Indications
1. palliative treatmentof large
obstructing central airway tumors
(NSCLC).
2. Metastatic airway tumors.
3. Early NSCLC that is limited to the
airway.
4. Benign tracheal stenosis
19.
Palliation of centralobstructing airway
tumors
Palliation of obstructive symptoms caused by large
central airway tumors that are not amenable to
surgical resection and/orEBRT.
Patients cannot tolerate or fail other local ablative
therapies (Nd:YAG laser, APC, or cryotherapy).
20.
Types of cancerthat are responsive to EBBT
Biopsy proven NSCLC
Early NSCLC localized to the airway.
Positive resection margins or a stump
Recurrence following surgery.
Extrathoracic malignancy metastatic to lung
Small cell carcinoma/carcinoid (no response)
Palliation of central obstructing airway
tumors
Acute life threateningsymptoms of airway obstruction
First-: local ablative therapies or EBRT
Followed by EBBT
• Efficacy:
Subjective and objective improvement following
EBBT (20 to 100 % of patients).
No survival benefit associated with EBBT or EBBT in
combination with chemotherapy.
EBBT + Coventional methods (beneficial)
Palliation of central obstructing airway
tumors
24.
Hemoptysis improvemost readily (90% response
rate)
Cough and dyspnea may improve less reliably,
(underlying conditions such as COPD or radiation
fibrosis).
Responses in tumor size and the degree of airway
obstruction are most commonly evaluated by chest
radiography and bronchoscopy.
70 % of patients have greater than 50% improvement
in patency that persists for at least six months.
Palliation of central obstructing airway
tumors
25.
Benign airway stenosis
Recurrenttracheal stenosis
Following repeated attempts at dilation and stenting,
HDR EBBT (eg, a single 3 to 10Gray [Gy] dose of
Iridium192) is beneficial.
Prevents formation of granulation tissue and reduce
the recurrence rate of restenosis.
Role in post TB stenosis ???
28.
Contraindications- Absolute
1) presenceof fistulas between bronchi and
other structures.
(EBBT increases the risk of viscus rupture and
fatal hemorrhage)
2) Presence of high grade airway obstruction.
Try other modalities first
use of brachytherapy will not immediately
shrink tumor size
(maximal effect is after three weeks)
may result in postradiation tissue edema and
complete airway obstruction.
29.
Moribund patients.
Other absolute
contraindications to
bronchoscopy in general.
Contraindications- Absolute
30.
1. Lesions inclose proximity to large
vessels
2. Malignant involvement of the major
arteries
3. Significant destruction of the bronchial
wall
4. Mediastinal invasion
Contraindications- Relative
High risk of fistula formation and fatal hemorrhage
31.
Complications
<5%. Range(5-40%)
Early (hours to days) or late (days
to weeks).
Early:
Infrequent
Usually due to bronchoscopy or
catheter insertion.
Hemoptysis
Catheter displacement
Early complications of
bronchoscopy
Conclusions (EBBT)
Placementof a radioactive source
within or in close proximity to a
malignancy in order to provide high
doses of radiation close to the tumor.
EBBT is a good palliative treatment
for endoluminal neoplasms of the
lungs, either alone or in combination
with other procedures.
34.
Used inbenign airway stenosis.
HDR/LDR EBBT
Bronchoscopy guided procedure.
Combined with EBRT/APC/Nd YAG
(better results)
Good tolerance and low
complication rate.
Conclusions